Changing The Diabetes Care Paradigm With Arecor's Dr. Sarah Howell
While renal disease treatment technologies have seen moderate incremental improvements, there hasn't been a step-change advance in diabetes care since the discovery of insulin more than 100 years ago. Working with manufacturers of existing diabetes therapeutics in addition to advancing its own pipeline, Arecor is developing enhanced reformulations of tried-and-true therapeutics like insulin to improve a long-static standard of care. Arecor CEO Sarah Howell, Ph.D. joins the Business of Biotech for a discussion on the company's approach to improving the quality of life for some 200 million insulin-dependent patients worldwide.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.